Accelerate Efficiency By Decoupling Collection From Manufacturing

Early-stage cell and gene therapy manufacturing frequently relies on fresh starting materials, creating an intense, synchronized rush between patient collection and facility processing. While manageable at a small scale, this rigid timeline becomes a major liability during expansion, where any transit delay or collection anomaly can lead to missed manufacturing slots and lost batches. Decoupling these two critical phases provides a strategic buffer, introducing flexibility and resilience into the advanced therapy supply chain.

Transitioning to a cryopreserved workflow allows developer facilities to receive, quality-test, and hold starting materials well ahead of scheduling production. This shift optimizes facility utilization, stabilizes labor demands, and dramatically reduces the risk of operational bottlenecks. Achieving this level of predictability requires meticulous temperature control, standardized handling protocols, and validated shipping networks to safeguard cellular viability.

Explore how decoupling collection from manufacturing mitigates risk and drives operational efficiency by reading the complete article.